Low Rates of Anaphylaxis Following Pfizer-BioNTech COVID-19 Vaccination
Anaphylaxis following administration of the Pfizer-BioNTech COVID-19 vaccine occurred at a rate of 11.1 per 1 million doses.
Allergies
AAAAI/ACAAI/CSACI Consensus Statement on Infant Food Allergy Prevention
The AAAAI, ACAAI, and the CSACI have published a consensus statement and recommendations on nutritional interventions for the prevention of food allergy.
Severe, Poorly Controlled Pediatric Asthma Worsened by Allergen Sensitization
Children with severe or poorly controlled asthma with allergen sensitization have been shown to experience more asthma exacerbations and use more oral corticosteroids compared with those without allergen sensitization.
Reopening Allergy/Immunology Services Based on a Phased Approach
In response to the COVID-19 pandemic, a phased approach for resuming suspended allergy/immunology clinical services is advised, according to consensus recommendations.
ACAAI: Statement on Corticosteroid Use for Allergies, Asthma During COVID-19 Pandemic
The American College of Allergy, Asthma and Immunology (ACAAI) has issued a statement regarding the use of corticosteroids for patients with allergies and asthma.
High-Risk Phenotype Identified for Acute Exacerbation of Chronic Rhinosinusitis
Patients with acute exacerbations of chronic rhinosinusitis have appear to have a high-risk phenotype.
FDA Approves First Treatment for Peanut Allergy
The Food and Drug Administration (FDA) has approved Palforzia (Peanut [Arachis hypogaea] Allergen Powder-dnfp; Aimmune Therapeutics) for the treatment of peanut allergy.
How Does the Rising Cost of EpiPen Affect Patients and Providers?
Researchers sough to assess whether the cost of the EpiPen affected patient emergency department visits and length of hospital stay before and after the implementation of the Affordable Care Act.
EAACI Position Paper on the Role of Mobile Heath in Allergy Management
A task force created by the European Academy of Allergy and Clinical Immunology released recommendations and an action plan for the potential of mobile health in allergology.
Antihistamine-Releasing Contact Lens Looks Promising in Phase 3 Trials
Results from two phase 3 studies evaluating an investigational antihistamine-releasing contact lens (etafilcon A with ketotifen 0.019mg) showed that the treatment may benefit patients who need vision correction and also suffer from ocular allergies.
-
Loading...
-
Loading...
Next post in Allergy and Immunology Information Center
